Anika Therapeutics (ANIK) 10-Q2019 Q1 Quarterly report

Filed: 6 May 19, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adhesion, arebased, Bedford, book, borrow, borrowing, classification, collateral, collateralized, concept, core, define, depreciated, depreciation, EBITDA, economic, equivalent, exclusion, feet, foreseeable, heading, HYALOSPINE, implicit, index, instance, instrumentation, isolation, light, main, masked, MEROGEL, methodology, minimum, monitor, monthly, moving, nearest, nonlease, Notwithstanding, Padova, past, pay, portion, preceding, prescribed, proof, readily, reassessed, reassessment, reconciliation, reflect, reflected, refreshing, remeasure, renew, rent, requisite, restate, room, salary, schedule, shortfall, shown, similarly, space, spinal, square, target, titled, training, transparency, type, unamortized, warehousing

Removed: accept, adjustment, allocating, allocation, Amherst, assure, begin, Bulletin, capable, Codification, collaborate, collect, collected, commercialize, competitive, consistent, constraint, consulting, contingent, continued, cumulative, customary, deemed, delay, deposit, determination, directly, discovery, discretion, distinct, earliest, enforced, enterprise, executed, expenditure, failure, FOB, forecasting, free, funded, guarantee, handling, hip, identification, improve, improvement, incentive, initially, Institute, Internally, iv, labeling, law, leasing, legislation, licensee, local, maker, manufacture, matrix, mitigation, mix, modality, nature, observable, obtained, obtaining, occur, offered, optional, payment, percentage, planning, practice, predominant, prevailing, principally, promise, promised, prospective, raw, recognize, reform, regularly, remediation, resell, resignation, resolve, resource, rest, resume, retired, return, reversal, reviewed, rheumatoid, royalty, sale, sample, satisfied, segment, setting, shipping, significantly, simplify, sought, stated, subsequently, surveillance, tiered, timeline, tracking, transaction, transferred, unanticipated, uncertainty, unforeseen, vary, volume, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ANIK transcripts

ANIK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned officers of Anika Therapeutics, Inc. (the “Company”) hereby certify to their knowledge and in their respective capacities that the Company’s quarterly report on Form 10-Q to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 3, 2019		/s/ JOSEPH G. DARLING
		Joseph G. Darling.
		President and Chief Executive Officer
		Principal Executive Officer


Date: May 3, 2019		/s/ SYLVIA CHEUNG
		Sylvia Cheung
		Chief Financial Officer
		Principal Financial Officer

This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing, under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.